Investigation of TRPM7 Immunoreactivity as a Biomarker to Predict Treatment-Resistant Endometrial Hyperplasia:A Retrospective Case-Control Study

ABS TRACT Objective: In our study, we investigated transient receptor potential melastatin 7 (TRPM7) immunoreactivity in pre- and posttreatment pathology samples of patients with endometrial hyperplasia (EH) who responded to progesterone therapy were resistant therapy. Material Methods: this retrospective, comparative single-center case-control tissue TRPM7 was evaluated sections obtained from paraffin blocks 60 cases diagnosed EH proliferative endometrium. Randomly selected endometrium group for control [(Group(G)1, n=20)], The first [(G2, n=20)] second [(G3, biopsy results the recovered [(G4, [(G5, that but did not recover treatment. SPSS version 22 program (SPSS Inc., Chicago, IL) used statistical analysis. Intergroup evaluation carried out one-way ANOVA post-hoc tukey test. p<0.05 values considered statistically significant. Results: found be significantly increased G2, G4, G5 compared G1. However, no significant difference observed between G5. When these groups, decreased G3, it similar Conclusion: cases, unchanged before after treatment may an immunohistochemical biomarker determining resistance